At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene
In Brief
A Phase 2 clinical trial evaluating Placebo and Enclomiphene for Acquired Hypogonadotropic Hypogonadism and Obesity. Completed, enrolled 50 participants across 5 sites.
Detailed Summary
The purpose of this study is to compare the effects of 12 months of treatment with enclomiphene 12.5 mg, 25 mg, or placebo capsules on body composition and metabolic parameters in overweight men with acquired hypogonadotropic hypogonadism \[confirmed morning testosterone (T) ≤300 ng/dL\] following a 6 month diet and 15 month exercise program.
Study Details
Timeline
Interventions
One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
Enclomiphene capsule daily in the morning with approximately 8 ounces of water for up to 12 months.